Tepid response to Leqembi launch from US pricing overseer

The influential Institute for Clinical and Economic Review (ICER), a Boston, USA-based pricing watchdog, has released a report into the cost-effectiveness of Leqembi (lecanemab).

Summing up the findings, chief medical officer David Rind said the data “strongly suggests that lecanemab mildly slows the loss of cognition in patients with early Alzheimer’s disease.”

However, he added, “given the risks of brain swelling and bleeding, particularly when lecanemab is used outside of clinical trials, we have some uncertainties as to whether the average benefits of lecanemab exceed its risks.”